VistaGen Therapeutics (NASDAQ:VTGN) Shares Cross Below Fifty Day Moving Average – What’s Next?

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.61 and traded as low as $0.5570. VistaGen Therapeutics shares last traded at $0.5976, with a volume of 551,172 shares changing hands.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on VTGN shares. Stifel Nicolaus downgraded VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price target for the company. in a report on Wednesday, December 17th. William Blair reaffirmed a “market perform” rating on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th. Jefferies Financial Group reiterated a “hold” rating and set a $0.90 price objective (down from $15.00) on shares of VistaGen Therapeutics in a report on Wednesday, December 17th. Maxim Group reaffirmed a “hold” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Finally, Wall Street Zen raised VistaGen Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, VistaGen Therapeutics presently has a consensus rating of “Reduce” and an average target price of $0.95.

VistaGen Therapeutics Stock Down 2.2%

The firm’s 50-day moving average price is $0.61 and its 200 day moving average price is $2.50. The company has a market capitalization of $23.68 million, a P/E ratio of -0.32 and a beta of 0.29.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its earnings results on Thursday, February 12th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.06. The business had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.14 million. As a group, equities research analysts expect that VistaGen Therapeutics, Inc. will post -1.77 EPS for the current year.

Institutional Trading of VistaGen Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in shares of VistaGen Therapeutics in the fourth quarter valued at approximately $25,000. Cubist Systematic Strategies LLC bought a new stake in VistaGen Therapeutics during the first quarter worth $25,000. Schonfeld Strategic Advisors LLC purchased a new stake in VistaGen Therapeutics in the 3rd quarter valued at $39,000. Seven Fleet Capital Management LP purchased a new stake in VistaGen Therapeutics in the 4th quarter valued at $42,000. Finally, Tudor Investment Corp ET AL bought a new position in VistaGen Therapeutics during the 4th quarter valued at $50,000. 78.39% of the stock is owned by hedge funds and other institutional investors.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.